BiotechTube
Home/Pipeline/Synergies with Cell Therapies

Synergies with Cell Therapies

Not Specified

ResearchResearch

Key Facts

Indication
Not Specified
Phase
Research
Status
Research
Company
Phio Pharmaceuticals

About Phio Pharmaceuticals

Phio Pharmaceuticals is a clinical-stage biotech company leveraging its proprietary INTASYL self-delivering siRNA platform to develop next-generation immuno-oncology therapies. Founded on Nobel laureate Craig Mello's RNAi discovery, the company has pivoted from discovery to development, advancing lead candidates PH-762 (PD-1 silencer) and PH-894 (BRD4 silencer) through early clinical trials. Its strategy focuses on overcoming delivery challenges in RNAi to enhance immune cell function and directly attack tumors, aiming to create synergistic treatments for cancers like cutaneous squamous cell carcinoma and melanoma.

View full company profile

Therapeutic Areas

OncologyImmuno-Oncology

Other Not Specified Drugs

DrugCompanyPhase
New TCM FormulationsChina SXT PharmaceuticalsResearch / Pre-clinical
Long-acting LeronlimabCytoDynPreclinical
Collaborative Program with FerringPharmaBiomeResearch
Lighthouse Pilot ProductCipheromePilot
Nitric Oxide + Collagen DeliveryJellagenResearch
UndisclosedAutheraPre-clinical
BP1003Bio-Path HoldingsPreclinical
mRNA Therapeutics Platform ApplicationLupagenResearch
PHYRAGOHanda PharmaceuticalsApproved
TASCENSO ODTHanda PharmaceuticalsApproved
AxulinHousey Pharmaceutical Research LaboratoriesCommercial
PBI-04711Phoenix BiotechnologyPre-clinical